SRH Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

SRH Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-500	Closed	-$4.49K	–	271
2024 Q4	$4.49K	Hold	500	–	–	﹤0.01%	250
2024 Q3	$3.67K	Hold	500	–	–	﹤0.01%	261
2024 Q2	$2.85K	Hold	500	–	–	﹤0.01%	270
2024 Q1	$2.5K	Hold	500	–	–	﹤0.01%	292
2023 Q4	$4.5K	Hold	500	–	–	﹤0.01%	258
2023 Q3	$3.88K	Hold	500	–	–	﹤0.01%	256
2023 Q2	$5.48K	Hold	500	–	–	﹤0.01%	240
2023 Q1	$5K	Hold	500	–	–	﹤0.01%	244
2022 Q4	$2K	Hold	500	–	–	﹤0.01%	276
2022 Q3	$4K	Hold	500	–	–	0.01%	263
2022 Q2	$5K	Hold	500	–	–	0.01%	246
2022 Q1	$6K	Hold	500	–	–	0.01%	244
2021 Q4	$11K	Sell	500 -500	-50%	-$11.8K	0.01%	210
2021 Q3	$22K	Hold	1,000	–	–	0.03%	166
2021 Q2	$13K	Hold	1,000	–	–	0.02%	196
2021 Q1	$13K	Buy	+1,000	New	+$14.5K	0.02%	189

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SRH Advisors's AUPH Position: Q1 2025 in Review

SRH Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2025, closing a stake of 500 shares — an estimated $4.49K sold.

SRH Advisors first reported a position in AUPH in Q1 2021 and held it in 16 quarters. The position peaked at $22K in Q3 2021. 214 funds tracked by Wall St. Rank hold AUPH as of Q1 2025.

SRH Advisors reported no remaining Aurinia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
SRH Advisors sold 500 Aurinia Pharmaceuticals shares in Q1 2025, an estimated $4.49K.
SRH Advisors first reported a position in Aurinia Pharmaceuticals in Q1 2021 and held it in 16 quarters.
SRH Advisors's Aurinia Pharmaceuticals position peaked at $22K in Q3 2021.
214 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2025.

Based on SRH Advisors's 13F filing for Q1 2025, filed 5 May 2025.